Encore Medical, INC. (EMI) — SEC Filings

Overview

Encore Medical, INC. (EMI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a FWP filed on Mar 25, 2026: Encore Medical, Inc. (CIK: 0001838003) filed a Free Writing Prospectus (FWP) on March 25, 2026, under Securities Act Rules 163/433. This filing, with SEC Accession No. 0001104659-26-034401, includes 22 documents, primarily graphics, and relates to their business as a surgical and medical instruments

Sentiment Summary

Across 5 filings, the sentiment breakdown is: 1 bearish, 2 neutral, 2 mixed. The dominant filing sentiment for Encore Medical, INC. is neutral.

Filing Type Overview

Encore Medical, INC. (EMI) has filed 3 S-1/A, 1 FWP, 1 S-1 with the SEC between Sep 2025 to Apr 2026.

Filings by Year

2026 · 2025

Recent Filings (5)

• S-1/A Filing — S-1/A · Apr 4, 2026
• Encore Medical Files FWP, Signaling Potential Capital Raise — FWP · Mar 25, 2026
  Encore Medical, Inc. (CIK: 0001838003) filed a Free Writing Prospectus (FWP) on March 25, 2026, under Securities Act Rules 163/433. This filing, with SEC Access
• Encore Medical IPO Targets $15M for US Clinical Trials — S-1/A · Mar 24, 2026 Risk: high
  Encore Medical, Inc. (EMI) is launching an initial public offering of 3,000,000 shares of common stock at an expected price of $5.00 per share, aiming to raise
• Encore Medical IPO Targets $15M to Fund US Cardiac Device Trials — S-1/A · Dec 30, 2025 Risk: high
  Encore Medical, Inc. (EMI) is launching an initial public offering of 3,000,000 shares at an expected price of $5.00 per share, aiming to raise $15,000,000 befo
• Encore Medical IPO Targets $1.5B US Stroke Market Amidst High Risk — S-1 · Sep 15, 2025 Risk: high
  Encore Medical, Inc. (EMI) is launching its initial public offering to fund U.S. clinical trials for its PFO septal occlusion device, targeting stroke and migra

Risk Profile

Risk Assessment: Of EMI's 3 recent filings, 3 were flagged as high-risk, 0 as medium-risk, and 0 as low-risk. The overall risk profile suggests elevated risk that warrants close monitoring.

Key Executives

• Joseph A. Marino
• Amy Bowler
• William M. Mower
• Andrew M. Tataryn

Industry Context

The transcatheter cardiac device market is highly competitive, dominated by large, established medical device companies with significant R&D and sales infrastructure. Encore aims to enter the U.S. market for PFO closure, a segment with potential for growth driven by increasing awareness of stroke and migraine links to PFOs. However, regulatory hurdles and the need for extensive clinical validation are significant barriers to entry.

Top Tags

IPO (3) · Medical Devices (3) · Structural Heart (3) · FDA Approval (3) · PFO Closure (3) · Emerging Growth Company (3) · Clinical Trials (2) · free-writing-prospectus (1) · capital-raise (1) · securities-offering (1)

Key Numbers

• Total initial public offering price: $15,000,000 — Expected gross proceeds from selling 3,000,000 shares at $5.00 per share
• Underwriting discounts and commissions: $1,200,000 — 8% of the total offering price, paid to underwriters
• Proceeds, before expenses, to Encore Medical, Inc.: $13,800,000 — Net proceeds from the IPO after underwriting fees
• Shares of common stock offered: 3,000,000 — Number of shares being sold in the initial public offering
• Expected initial public offering price per share: $5.00 — Price at which each share of common stock is expected to be sold
• Underwriter's fee: 8% — Percentage of the amount raised paid to underwriters
• Over-allotment option shares: 450,000 — Additional shares underwriters can purchase within 45 days
• Successful transcatheter defect closure implants: 35,000 — Number of implants performed outside the U.S. using Encore's technology
• Assumed average sales price per PFO product: $11,000 — Used to estimate the potential annual market for PFO products for stroke prevention
• Ending cash balance as of December 31, 2025: $94,256.00 — Indicates limited cash reserves prior to the IPO
• Additional shares for over-allotment option: 450,000 — Underwriters' option to purchase more shares within 45 days
• Approximate number of patients implanted: 35,000 — Number of patients who have received Encore Medical's septal occlusion devices outside the U.S.
• Potential annual U.S. market for PFO products for stroke prevention: $1.5 billion — Estimated market size based on 139,000 patients and an $11,000 average sales price
• Estimated time to complete FDA clinical trial: 2 years — Projected duration for the U.S. clinical trial for PFO septal occlusion device for stroke
• Assumed average sales price per product: $11,000 — Used to calculate the potential U.S. market for PFO products for stroke prevention

Related Companies

ABT · GORE

Frequently Asked Questions